In human prostate cancer, MYC drove glucose metabolism via the suppression of TXNIP (a potent negative regulator of glucose uptake), which was predominantly dependent on the glutaminase-MondoA axis [35]. The gene discussed is TXNIP; the disease is prostate carcinoma.